Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Adverse perinatal outcome (1)
- Adverse pregnancy outcome (1)
- Antiepileptic drugs (1)
- Combining outcomes (1)
- Costs (1)
-
- Counterfeit drug (1)
- FDA (1)
- Health Economics (1)
- Health Information Systems Research (1)
- Health insurance (1)
- Healthcare (1)
- Latent trait model (1)
- Managed care (1)
- Medical services (1)
- Other Pharmacy Practice (1)
- Patient safety (1)
- Payments (1)
- Pharmaceutical (1)
- Pharmacists (1)
- Pharmacy services (1)
- RFID (1)
- Reimbursement (1)
- Supply chain (1)
- Valproate (1)
- Publication
- File Type
Articles 1 - 5 of 5
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Reliability And Credibility Of Progress Test Criteria, Developed By Alumni, Faculty, And Mixed Alumni-Faculty Judge Panels, H. Glenn Anderson Pharmd, Arthur A. Nelson Phd
Reliability And Credibility Of Progress Test Criteria, Developed By Alumni, Faculty, And Mixed Alumni-Faculty Judge Panels, H. Glenn Anderson Pharmd, Arthur A. Nelson Phd
H. Glenn Anderson
Objective. To compare the reliability and credibility of Angoff-based, absolute criteria derived by faculty, alumni, and a combination of alumni and faculty judge panels. Methods. Independently, faculty, alumni, and mixed faculty-alumni judge panels developed pass/fail criteria for an 86-item test. Generalizability and decision studies were performed. Root mean square errors (RMSE) and 95% confidence intervals were calculated for reliability and credibility assessment. School graduate performance upon the North American Licensure Examination (NAPLEX) was the comparator for credibility assessment. Results. RMSEs were 1.06%, 1.42%, and 2.32% for the alumni, faculty, and mixed judge panels respectively. The school's NAPLEX pass rate was …
Combining Adverse Pregnancy And Perinatal Outcomes For Women Exposed To Antiepileptic Drugs During Pregnancy, Using A Latent Trait Model, Xuerong Wen
XUERONG Wen
Reimbursement For Pharmaceutical Care Services: The California Experience, Jeffery A. Goad, Kathleen Johnson, Michael Rudolph
Reimbursement For Pharmaceutical Care Services: The California Experience, Jeffery A. Goad, Kathleen Johnson, Michael Rudolph
Jeff Goad
"While it is true that pharmacists are changing their practice habits, they are doing so for the betterment of their patients’ drug therapy outcomes and the healthcare system. The pharmacist serves as the vital link between the patient, physician, and healthcare system. By working with patients and physicians, pharmacists have demonstrated in the literature that they can improve patient drug therapy outcomes, thus preventing unnecessary healthcare expenditures (Fincham, 1998). Pharmacists have long been held in highest esteem by patients, being voted the number one trusted professional for 10 consecutive years. The evidence is clear that pharmacists provide a valuable service …
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, Alberto Coustasse, Cody Arvidson, Phil Rutsohn
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, Alberto Coustasse, Cody Arvidson, Phil Rutsohn
Alberto Coustasse, DrPH, MD, MBA, MPH
Both nationally and internationally, pharmaceutical counterfeiting has become a problem that is threatening economic stability and public health. The purpose of the present research study review was to analyze the scope and severity of pharmaceutical counterfeiting and to establish if the implantation of the Radio Frequency Identification Device (RFID) model can more efficiently be used within the pharmaceutical supply chain to reduce the problem counterfeit drugs impose on public health and international economic stability. Results indicated that implementing the RFID model for tracking drugs at the item level in the pharmaceutical supply chain has potential to alleviate the scope of …
Dynamic Cost-Effectiveness Of Oncology Drugs, Yang Lu, John Penrod, Neeraj Sood, Saarah Woodby, Tomas Philipson
Dynamic Cost-Effectiveness Of Oncology Drugs, Yang Lu, John Penrod, Neeraj Sood, Saarah Woodby, Tomas Philipson
Yang Lu
Objective: To develop a methodology for computing cost-effectiveness measures of a drug throughout its life cycle.
Study Design: We developed a set of models that measure the long-term cost-effectiveness of 2 oncology drugs, paclitaxel and docetaxel, throughout their life cycles.
Methods: The study combined pricing history of the drugs, US Food and Drug Administration approval dates, drug utilization from Medicare claims, and clinical effectiveness information from phase III studies reported in the scientific literature. These data were used to estimate the incremental cost-effectiveness ratio (ICER) at the time of market entry and by year thereafter. The study population included patients …